Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

@article{Mease2011AbataceptIT,
  title={Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.},
  author={Philip J Mease and Mark C Genovese and Geoffrey Gladstein and Alan J. Kivitz and Christopher J Ritchlin and Paul Peter Tak and Juergen Wollenhaupt and Orna Bahary and J. Becker and Sheila J Kelly and Leonard Sigal and Julie Teng and Dafna Gladman},
  journal={Arthritis and rheumatism},
  year={2011},
  volume={63 4},
  pages={939-48}
}
OBJECTIVE To assess the safety and efficacy of abatacept, a selective T cell costimulation modulator, in patients with psoriatic arthritis (PsA). METHODS In this 6-month, multicenter, randomized, double-blind, placebo-controlled, phase II study, 170 PsA patients with a psoriasis target lesion (TL) ≥2 cm who had previously taken disease-modifying antirheumatic drugs (DMARDs), including anti-tumor necrosis factor (anti-TNF) agents, were randomized (1:1:1:1) to receive placebo or abatacept at… CONTINUE READING